Role of Hyperthermic Intraperitoneal Chemotherapy Combined with Cytoreductive Surgery as Consolidation Therapy for Advanced Epithelial Ovarian Cancer.
Humans
Female
Aged
Carcinoma, Ovarian Epithelial
/ therapy
Hyperthermic Intraperitoneal Chemotherapy
Cytoreduction Surgical Procedures
/ methods
Prospective Studies
Retrospective Studies
Combined Modality Therapy
Consolidation Chemotherapy
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Hyperthermia, Induced
/ methods
Peritoneal Neoplasms
/ therapy
Ovarian Neoplasms
/ surgery
Survival Rate
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
23
08
2022
accepted:
28
12
2022
medline:
15
5
2023
pubmed:
24
2
2023
entrez:
23
2
2023
Statut:
ppublish
Résumé
Patients with advanced epithelial ovarian cancer who undergo incomplete surgery followed by six cycles of chemotherapy could benefit from second-look or consolidation cytoreductive surgery (CCRS). The primary goal of this study was to evaluate the overall survival (OS) in patients undergoing complete CCRS and the factors affecting survival. The secondary goal was to study the benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in these patients. This was a retrospective analysis of 173 patients with CCRS with (n = 118) or without (n = 55) HIPEC treated at 12 French centers. Only patients having a completeness of cytoreduction (CC) 0/1 resection and a minimum of 5 years of follow-up were included. HIPEC was performed systematically for all patients except those treated at the four centers that did not perform HIPEC. The median Peritoneal Cancer Index was 6 (range 0-33). Closed HIPEC was performed in 59 (34.1%) patients and open HIPEC was performed in 56 (32.3%) patients. Grade 3-4 complications occurred in 64 (36.9%) patients. The median OS was 35.67 months (95% confidence interval [CI] 29.8-46.1) and was significantly longer for CCRS + HIPEC (31.4 months without HIPEC and 42.5 months with HIPEC; p = 0.022). On multivariate analysis, closed HIPEC (hazard ratio [HR] 0.46, 95% CI 0.29-0.73; p < 0.001) resulted in a longer OS, and age > 65 years (HR 2.17, 95% CI 1.14-4.11; p = 0.018) and bowel resection (HR 1.98, 95% CI 1.27-3.08; p = 0.020) led to a shorter OS. On multivariate logistic regression analysis, closed HIPEC (odds ratio 0.18; p = 0.001) was associated with a lower risk of dying at 5 years. CCRS was performed with an acceptable morbidity and resulted in good overall survival. The role of HIPEC in addition to CCRS should be evaluated in prospective, randomized studies and the closed technique prospectively compared with the open technique.
Sections du résumé
BACKGROUND
BACKGROUND
Patients with advanced epithelial ovarian cancer who undergo incomplete surgery followed by six cycles of chemotherapy could benefit from second-look or consolidation cytoreductive surgery (CCRS). The primary goal of this study was to evaluate the overall survival (OS) in patients undergoing complete CCRS and the factors affecting survival. The secondary goal was to study the benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in these patients.
METHODS
METHODS
This was a retrospective analysis of 173 patients with CCRS with (n = 118) or without (n = 55) HIPEC treated at 12 French centers. Only patients having a completeness of cytoreduction (CC) 0/1 resection and a minimum of 5 years of follow-up were included. HIPEC was performed systematically for all patients except those treated at the four centers that did not perform HIPEC.
RESULTS
RESULTS
The median Peritoneal Cancer Index was 6 (range 0-33). Closed HIPEC was performed in 59 (34.1%) patients and open HIPEC was performed in 56 (32.3%) patients. Grade 3-4 complications occurred in 64 (36.9%) patients. The median OS was 35.67 months (95% confidence interval [CI] 29.8-46.1) and was significantly longer for CCRS + HIPEC (31.4 months without HIPEC and 42.5 months with HIPEC; p = 0.022). On multivariate analysis, closed HIPEC (hazard ratio [HR] 0.46, 95% CI 0.29-0.73; p < 0.001) resulted in a longer OS, and age > 65 years (HR 2.17, 95% CI 1.14-4.11; p = 0.018) and bowel resection (HR 1.98, 95% CI 1.27-3.08; p = 0.020) led to a shorter OS. On multivariate logistic regression analysis, closed HIPEC (odds ratio 0.18; p = 0.001) was associated with a lower risk of dying at 5 years.
CONCLUSIONS
CONCLUSIONS
CCRS was performed with an acceptable morbidity and resulted in good overall survival. The role of HIPEC in addition to CCRS should be evaluated in prospective, randomized studies and the closed technique prospectively compared with the open technique.
Identifiants
pubmed: 36820940
doi: 10.1245/s10434-023-13242-8
pii: 10.1245/s10434-023-13242-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3287-3299Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2023. Society of Surgical Oncology.
Références
Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20(5):1248–59.
doi: 10.1200/JCO.2002.20.5.1248
pubmed: 11870167
Earle CC, Schrag D, Neville BA, Yabroff KR, Topor M, Fahey A, et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst. 2006;98(3):172–80. https://doi.org/10.1093/jnci/djj019 .
doi: 10.1093/jnci/djj019
pubmed: 16449677
Rose PG, Nerenstone S, Brady MF, Clarke-Pearson D, Olt G, Rubin SC, Gynecologic Oncology Group, et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med. 2004;351(24):2489–97. https://doi.org/10.1056/NEJMoa041125 .
doi: 10.1056/NEJMoa041125
pubmed: 15590951
Obermair A, Sevelda P. Impact of second look laparotomy and secondary cytoreductive surgery at second-look laparotomy in ovarian cancer patients. Acta Obstet Gynecol Scand. 2001;80(5):432–6.
doi: 10.1034/j.1600-0412.2001.080005432.x
pubmed: 11328220
Greer BE, Bundy BN, Ozols RF, et al. Implications of second-look laparotomy in the context of optimally resected Stage III ovarian cancer: a nonrandomized comparison using an explanatory analysis: a GOG study. Gynecol Oncol. 2005;99:71–9.
doi: 10.1016/j.ygyno.2005.05.012
pubmed: 16039699
Thigpen T. The if and when of surgical debulking for ovarian carcinoma. N Engl J Med. 2004;351(24):2544–6. https://doi.org/10.1056/NEJMe048292 .
doi: 10.1056/NEJMe048292
pubmed: 15590959
Rahaman J, Dottino P, Jennings TS, et al. The second-look operation improves survival in suboptimally debulked stage III ovarian cancer patients. Int J Gynecol Cancer. 2005;15:19–25.
doi: 10.1111/j.1048-891X.2005.15003.x
pubmed: 15670292
Tournigand C, Louvet C, Molitor JL, Fritel X, Dehni N, Sezeur A, et al. Long-term survival with consolidation intraperitoneal chemotherapy for patients with advanced ovarian cancer with pathological complete remission. Gynecol Oncol. 2003;91(2):341–5. https://doi.org/10.1016/s0090-8258(03)00474-8 .
doi: 10.1016/s0090-8258(03)00474-8
pubmed: 14599864
Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009;114(1):26–31. https://doi.org/10.1016/j.ygyno.2009.03.018 .
doi: 10.1016/j.ygyno.2009.03.018
pubmed: 19395008
Reverdy T, Sajous C, Péron J, Glehen O, Bakrin N, Gertych W, et al. Front-line maintenance therapy in advanced ovarian cancer-current advances and perspectives. Cancers. 2020;12(9):2414. https://doi.org/10.3390/cancers12092414 .
doi: 10.3390/cancers12092414
pubmed: 32854393
pmcid: 7564452
van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230–40. https://doi.org/10.1056/NEJMoa1708618 .
doi: 10.1056/NEJMoa1708618
pubmed: 29342393
Mendivil AA, Rettenmaier MA, Abaid LN, Brown JV 3rd, Mori KM, Lopez KL, et al. Consolidation hyperthermic intraperitoneal chemotherapy for the treatment of advanced stage ovarian carcinoma: a 3 year experience. Cancer Chemother Pharmacol. 2017;80(2):405–10. https://doi.org/10.1007/s00280-017-3376-8 .
doi: 10.1007/s00280-017-3376-8
pubmed: 28669065
Ko J, Ha HI, Choi MC, Jung SG, Park H, Joo WD, et al. Hyperthermic intraperitoneal chemotherapy as consolidation treatment of advanced stage ovarian cancer. Obstet Gynecol Sci. 2021;64(5):437–43. https://doi.org/10.5468/ogs.21093 .
doi: 10.5468/ogs.21093
pubmed: 34325503
pmcid: 8458613
Bakrin N, Bereder JM, Decullier E, Classe JM, Msika S, Lorimier G, et al. Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol. 2013;39(12):1435–43. https://doi.org/10.1016/j.ejso.2013.09.030 .
doi: 10.1016/j.ejso.2013.09.030
pubmed: 24209430
Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–74. https://doi.org/10.1007/978-1-4613-1247-5_23 .
doi: 10.1007/978-1-4613-1247-5_23
pubmed: 8849962
Sugarbaker PH. An overview of peritonectomy, visceral resections, and perioperative chemotherapy for peritoneal surface malignancy. In: PH Sugarbaker, editor. Cytoreductive surgery & perioperative chemotherapy for peritoneal surface malignancy. Textbook and Video Atlas. Woodbury: Cine-Med Publishing; 2012. p. 1–30.
Glehen O, Cotte E, Kusamura S, Deraco M, Baratti D, Passot G, et al. Hyperthermic intraperitoneal chemotherapy: Nomenclature and modalities of perfusion. J Surg Oncol. 2008;98:242–6. https://doi.org/10.1002/jso.21061 .
doi: 10.1002/jso.21061
pubmed: 18726885
Sugarbaker PH, Averbach AM, Jacquet P, et al. A simplified approach to hyperthermic intraoperative intraperitoneal chemotherapy (HIIC) using a self retaining retractor. In: PH Sugarbaker, editor., et al., Peritoneal carcinomatosis: principles of management. Boston: Springer; 1996.
Gouy S, Ferron G, Glehen O, Bayar A, Marchal F, Pomel C, et al. Results of a multicenter phase I dose-finding trial of hyperthermic intraperitoneal cisplatin after neoadjuvant chemotherapy and complete cytoreductive surgery and followed by maintenance bevacizumab in initially unresectable ovarian cancer. Gynecol Oncol. 2016;142(2):237–42. https://doi.org/10.1016/j.ygyno.2016.05.032 .
doi: 10.1016/j.ygyno.2016.05.032
pubmed: 27246305
Van der Speeten K, Lemoine L, Sugarbaker P. Overview of the optimal perioperative intraperitoneal chemotherapy regimens used in current clinical practice. Pleura Peritoneum. 2017;2(2):63–72. https://doi.org/10.1515/pp-2017-0003 .
doi: 10.1515/pp-2017-0003
pubmed: 30911634
pmcid: 6405035
Elias D, Bonnay M, Puizillou JM, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol. 2002;13:267–72.
doi: 10.1093/annonc/mdf019
pubmed: 11886004
Quenet F, Goéré D, Mehta S, Roca L, Dumont F, Hessissen M, et al. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis. Ann Surg. 2011;254(2):294–301. https://doi.org/10.1097/SLA.0b013e3182263933 .
doi: 10.1097/SLA.0b013e3182263933
pubmed: 21772129
Common Terminology Criteria for Adverse Events (CTCAE). https://ctep.cancer.gov › protocoldevelopment› docs. Accessed 30 May 2022
Aloia TA, Zimmitti G, Conrad C, Gottumukalla V, Kopetz S, Vauthey JN. Return to intended oncologic treatment (RIOT): a novel metric for evaluating the quality of oncosurgical therapy for malignancy. J Surg Oncol. 2014;110(2):107–14. https://doi.org/10.1002/jso.23626 .
doi: 10.1002/jso.23626
pubmed: 24846705
pmcid: 5527828
Joneborg U, Palsdottir K, Farm E, Johansson H, Salehi S. Time-interval to adjuvant chemotherapy and postoperative management after upper abdominal surgical procedures in advanced ovarian cancer. Eur J Surg Oncol. 2021;47(2):353–9. https://doi.org/10.1016/j.ejso.2020.07.025 .
doi: 10.1016/j.ejso.2020.07.025
pubmed: 32778486
Kim HS, Park NH, Chung HH, Kim JW, Song YS, Kang SB. Are three additional cycles of chemotherapy useful in patients with advanced-stage epithelial ovarian cancer after a complete response to six cycles of intravenous adjuvant paclitaxel and carboplatin? Jpn J Clin Oncol. 2008;38(6):445–50. https://doi.org/10.1093/jjco/hyn034 .
doi: 10.1093/jjco/hyn034
pubmed: 18508785
pmcid: 2435294
Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, Gynecological Cancer Intergroup, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011;21(2):419–23. https://doi.org/10.1097/IGC.0b013e3182070f17 .
doi: 10.1097/IGC.0b013e3182070f17
pubmed: 21270624
Alcazer V. StatAid: an R package with a graphical user interface for data analysis. J Open Source Softw. 2020;5(54):2630. https://doi.org/10.21105/joss.02630 .
doi: 10.21105/joss.02630
Bacalbasa N, Balescu I, Dima S, Herlea V, David L, Brasoveanu V, et al. Initial incomplete surgery modifies prognosis in advanced ovarian cancer regardless of subsequent management. Anticancer Res. 2015;35(4):2315–20.
pubmed: 25862895
Sugarbaker PH. Peritoneum as the first-line of defense in carcinomatosis. J Surg Oncol. 2007;95(2):93–6. https://doi.org/10.1002/jso.20676 .
doi: 10.1002/jso.20676
pubmed: 17262739
Chu CS, Rubin SC. Second-look laparotomy for epithelial ovarian cancer: a reappraisal. Curr Oncol Rep. 2001;3:11–8. https://doi.org/10.1007/s11912-001-0037-0 .
doi: 10.1007/s11912-001-0037-0
pubmed: 11123864
Leiting JL, Cloyd JM, Ahmed A, Fournier K, Lee AJ, Dessureault S, et al. Comparison of open and closed hyperthermic intraperitoneal chemotherapy: results from the United States hyperthermic intraperitoneal chemotherapy collaborative. World J Gastrointest Oncol. 2020;12(7):756–67. https://doi.org/10.4251/wjgo.v12.i7.756 .
doi: 10.4251/wjgo.v12.i7.756
pubmed: 32864043
pmcid: 7428797
Quénet F, Elias D, Roca L, Goéré D, Ghouti L, Pocard M, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256–66. https://doi.org/10.1016/S1470-2045(20)30599-4 .
doi: 10.1016/S1470-2045(20)30599-4
pubmed: 33476595
Alyami M, Kim BJ, Villeneuve L, Vaudoyer D, Képénékian V, Bakrin N, et al. Ninety-day post-operative morbidity and mortality using the National Cancer Institute’s common terminology criteria for adverse events better describe post-operative outcome after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Int J Hyperthermia. 2018;34(5):532–7. https://doi.org/10.1080/02656736.2017.1367846 .
doi: 10.1080/02656736.2017.1367846
pubmed: 28838265
Esquis P, Consolo D, Magnin G, Pointaire P, Moretto P, Ynsa MD. High intra-abdominal pressure enhances the penetration and antitumor effect of intraperitoneal cisplatin on experimental peritoneal carcinomatosis. Ann Surg. 2006;244:106–12.
doi: 10.1097/01.sla.0000218089.61635.5f
pubmed: 16794395
pmcid: 1570583
Kusamura S, Azmi N, Fumagalli L, Baratti D, Guaglio M, Cavalleri A, et al. Phase II randomized study on tissue distribution and pharmacokinetics of cisplatin according to different levels of intra-abdominal pressure (IAP) during HIPEC (NCT02949791). Eur J Surg Oncol. 2021;47(1):82–8. https://doi.org/10.1016/j.ejso.2019.06.022 .
doi: 10.1016/j.ejso.2019.06.022
pubmed: 31262599
Chambers LM, Yao M, Morton M, Gruner M, Chichura A, Horowitz M, et al. Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Gynecol Oncol. 2021;161(2):389–95. https://doi.org/10.1016/j.ygyno.2021.01.039 .
doi: 10.1016/j.ygyno.2021.01.039
pubmed: 33551202
Sinukumar S, Damodaran D, Ray M, Mehta S, Paul L, Bhatt A. Pattern of recurrence after interval cytoreductive surgery and HIPEC following neoadjuvant chemotherapy in primary advanced stage IIIC/IVA epithelial ovarian cancer. Eur J Surg Oncol. 2021;47(6):1427–33. https://doi.org/10.1016/j.ejso.2021.01.013 .
doi: 10.1016/j.ejso.2021.01.013
pubmed: 33509612
Plett H, Filippova OT, Garbi A, Kommoss S, Rosendahl M, Langstraat C, et al. Role of delayed interval debulking for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer. An international multicenter study. Gynecol Oncol. 2020;159(2):434–41. https://doi.org/10.1016/j.ygyno.2020.08.028 .
doi: 10.1016/j.ygyno.2020.08.028
pubmed: 32919778
pmcid: 8371927
Liu YL, Zhou QC, Iasonos A, Chi DS, Zivanovic O, Sonoda Y, et al. Pre-operative neoadjuvant chemotherapy cycles and survival in newly diagnosed ovarian cancer: what is the optimal number? A Memorial Sloan Kettering Cancer Center Team Ovary study. Int J Gynecol Cancer. 2020;30(12):1915–21. https://doi.org/10.1136/ijgc-2020-001641 .
doi: 10.1136/ijgc-2020-001641
pubmed: 33106271
pmcid: 8407101